IP Library › Granted Patent US 11,602,555
Granted Patent B2
US 11,602,555 · App. 16/461,671 · Granted Mar 14, 2023

Treatment of respiratory tract diseases and infections with ascorbic acid compositions

Inventors: Dan Copeland (Chapel Hill, NC); Carolyn Durham (Chapel Hill, NC); Thomas E. Richardson (Chapel Hill, NC)
Assignee: RENOVION, INC.
A61K38/063A01N37/30A61K9/0073A61K9/19A61K45/06A61K47/02A61K47/22A61P11/00A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,602,555
App. No.
16/461,671
Granted
Mar 14, 2023
Kind
B2
Abstract

The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

Claims (11)

1. A method of treating or reducing symptoms in a subject suffering from bronchiectasis, wherein a clinical isolate bacteria chronic colonization infection occurs in the subject's airway, comprising administering to the subject's airway a composition comprising (i) glutathione, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and (ii) ascorbic acid, thereby contacting the clinical isolate, wherein the clinical isolate is Staphylococcus aureus , Methicillin-resistant Staphylococcus aureus (MRSA), or both, wherein the pH of the composition is about 6 to about 8; and wherein the subject is thereby treated or the symptoms reduced.

2. The method of claim 1 , wherein the clinical isolate comprises two or more clinical isolates.

3. The method of claim 1 , wherein the clinical isolate is Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus.

4. The method of claim 1 , wherein the clinical isolate is sensitized to an antibiotic to which the clinical isolate was tolerant or resistant prior to contact with the composition.

5. The method of claim 1 , wherein the clinical isolate comprises Methicillin-resistant Staphylococcus aureus (MRSA).

6. The method of claim 1 , wherein the glutathione comprises more than about 80% reduced glutathione by weight of total glutathione in the composition.

7. The method of claim 1 , wherein the ascorbic acid comprises more than about 80% reduced ascorbic acid by weight of total ascorbic acid in the composition.

8. The method of claim 1 , wherein the composition is administered to the subject twice daily.

9. The method of claim 1 , wherein the composition is an aqueous solution.

10. The method of claim 1 , wherein the pH of the composition is 7±1.5.

11. The method of claim 10 , wherein the composition is an aqueous solution.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: COPELAND, DAN; DURHAM, CAROLYN; RICHARDSON, THOMAS E.
To: RENOVION, INC.
Reel/Frame 061773/0065 →
Continuity (3)
Provisional Application 62423721 · Nov 17, 2016
Provisional Application 62423702 · Nov 17, 2016
Related Publication 20190351005A1 · Nov 21, 2019
Cited By (2)
US 12,419,932 US 12,427,180